5 billion! Establishment of a new Chinese medicine factory

5 billion yuan Yiling Pharmaceutical Co., Ltd has set up a wholly-owned subsidiary to produce Chinese herbal pieces and Chinese herbal formula granules In January this year, it just passed the clinical approval of 409 Chinese herbal formula granules A game of chess began Recently, Shijiazhuang Yiling Pharmaceutical Co., Ltd issued a notice, and the company deliberated and passed the proposal on the investment and construction of modern Chinese medicine industrialization projects by wholly-owned subsidiaries, investing 5.034 billion yuan in the construction of modern Chinese medicine industrialization projects According to the announcement, in order to further improve the company's comprehensive competitive strength and future sustainable development momentum, the company has formulated granules for traditional Chinese medicine Sufficient capacity reserves shall be made for the development of tablet agents, health products and other businesses On August 5, 2019, the company signed the agreement on entering the zone with the Management Committee of Hebei Gucheng Economic Development Zone, and reached an agreement on the construction and investment of Yiling pharmaceutical in Hebei Gucheng economic development zone On October 25, 2019, the company invested and established a wholly-owned subsidiary Hengshui Yiling Pharmaceutical Co., Ltd in Gucheng economic development zone It is understood that the main construction content of the project includes processing workshop, extraction workshop, preparation workshop, health product workshop, oil pressing workshop, boiler room, storage and other production and auxiliary facilities After the completion of the project, the annual production capacity of 4200 tons of Chinese herbal pieces, 4500 tons of formula granules, 4500 tons of Chinese herbal extracts, 3 billion pieces of Chinese herbal tablets and 1 billion soft capsules of Chinese herbal health products, 500 tons of health food and 1000 tons of health drink will be realized, which will lay a good foundation for the future development and market expansion of the company According to Yiling pharmaceutical, the construction of the project is based on the strategic consideration of the company's future development and is in line with the company's development strategy of growing and strengthening its main business It is not only conducive to further improving the strategic layout of the company's production base of traditional Chinese medicine and health industry, but also to expanding the production capacity of traditional Chinese medicine tablets, decoction pieces and health products It can also be used for the company's future development of traditional Chinese medicine formula particles and extract business Good production capacity reserve, so as to achieve the purpose of optimizing the company's product structure, is of great significance to enhance the company's core competitiveness Since 2015, the country has begun to vigorously develop traditional Chinese medicine, and the policy of "blowout" of traditional Chinese medicine is favorable In August of the same year, the outline of strategic plan for the development of traditional Chinese medicine (2016-2030) has defined the development direction and work focus of traditional Chinese medicine in the next 15 years, and the development of traditional Chinese medicine has been upgraded to the national strategy In December, China's first comprehensive law "Chinese medicine law" was promulgated, which comprehensively and systematically reflected the characteristics of traditional Chinese medicine Recently, the State Council issued the opinions on promoting the inheritance, innovation and development of traditional Chinese medicine, which raised the position of traditional Chinese medicine to a new height In the short term, the industry will experience a painful period of transformation and upgrading, which is conducive to the development of high-quality and standardized traditional Chinese Medicine enterprises in the long term In the future, it is a certain trend for the state to guide the traditional usage and encourage the oral varieties For example, Chinese herbal pieces may not be included in the drug centralized procurement catalogue, and the policy of not canceling the addition of Chinese herbal pieces and controlling the proportion of Chinese herbal pieces does not include Chinese herbal pieces is implemented Compared with Chinese herbal pieces, the quality standard of Chinese herbal formula granules is unified, which is convenient for large-scale production; the quantitative packaging and measurement of single drug are relatively accurate; the clinical formula can be formed with syndrome, which is convenient for use According to the public data, from 2006 to 2016, the sales volume of traditional Chinese medicine formula granules increased from 200 million yuan to 10.7 billion yuan, with an average annual compound growth rate of 48.9%, far higher than the growth of 26.7% of traditional Chinese medicine Pieces in the same period, and the proportion of traditional Chinese medicine formula granules in the sales volume of pieces gradually increased from 1% to 6% According to the industry data, in recent years, the market compound growth rate of traditional Chinese medicine formula granules has reached 30%, which is expected to reach 44 billion yuan in 2020, becoming one of the few subdivision areas in the pharmaceutical industry to maintain ultra-high growth Yiling Pharmaceutical Co., Ltd has invested 5 billion yuan in the distribution of traditional Chinese medicine formula granules, or has taken a fancy to this huge market It is understood that there are 409 varieties of formula granules in Yiling pharmaceutical industry have obtained the approval of clinical research of formula granules from Hebei food and drug administration, and more formula granules are constantly developed and put into the market In addition, the company has more than 120 sets of modern digital monitoring TCM extraction equipment certified by GMP, 12 automatic production lines of granules, and more than 400 commonly used clinical varieties of TCM formula granules, including Salvia miltiorrhiza, tangerine peel, angelica, hawthorn, liquorice, etc Yiling pharmaceutical industry forecasts that after the completion of the project, the annual sales revenue and net profit will be 5.77 billion yuan and 2.69 billion yuan respectively.